998 related articles for article (PubMed ID: 26378051)
21. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
[TBL] [Abstract][Full Text] [Related]
22. Screening of BRCA1/2 Mutations Using Direct Sequencing in Indonesian Familial Breast Cancer Cases.
Anwar SL; Haryono SJ; Aryandono T; Datasena IG
Asian Pac J Cancer Prev; 2016; 17(4):1987-91. PubMed ID: 27221885
[TBL] [Abstract][Full Text] [Related]
23. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
[TBL] [Abstract][Full Text] [Related]
24. Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer.
Noori SF; Gangi A; Nelson ME; Choi M; Mirzadehgan P; Bonk AK; Mirocha J; Amersi F; Giuliano AE
Ann Surg Oncol; 2014 Oct; 21(10):3324-9. PubMed ID: 25047471
[TBL] [Abstract][Full Text] [Related]
25. The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer.
Chen L; Fu F; Huang M; Lv J; Zhang W; Wang C
Breast Cancer Res Treat; 2020 Apr; 180(3):759-766. PubMed ID: 32072338
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological significance of β -tubulin isotype III gene expression in breast cancer patients.
He Q; Peng B; Zhuang D; Xiao L; Zheng L; Fan Z; Zhu J; Xu B; Xu C; Zhao J; Wu L; Zhou P; Hou L; Yu F; Zhao G
Cancer Biomark; 2015; 15(6):823-31. PubMed ID: 26406408
[TBL] [Abstract][Full Text] [Related]
27. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.
Arun B; Vogel KJ; Lopez A; Hernandez M; Atchley D; Broglio KR; Amos CI; Meric-Bernstam F; Kuerer H; Hortobagyi GN; Albarracin CT
Cancer Prev Res (Phila); 2009 Feb; 2(2):122-7. PubMed ID: 19174581
[TBL] [Abstract][Full Text] [Related]
28. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
29. Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling.
Salmon AY; Salmon-Divon M; Zahavi T; Barash Y; Levy-Drummer RS; Jacob-Hirsch J; Peretz T
Cancer Prev Res (Phila); 2013 Feb; 6(2):82-90. PubMed ID: 23341570
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
31. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
32. HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
van der Groep P; van Diest PJ; Smolders YH; Ausems MG; van der Luijt RB; Menko FH; Bart J; de Vries EG; van der Wall E
PLoS One; 2013; 8(2):e56055. PubMed ID: 23409121
[TBL] [Abstract][Full Text] [Related]
33. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing.
de la Cruz J; Andre F; Harrell RK; Bassett RL; Arun B; Mathieu MC; Delaloge S; Gilcrease MZ
Hum Pathol; 2012 Nov; 43(11):1932-9. PubMed ID: 22591913
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.
Zhang J; Pei R; Pang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Breast Cancer Res Treat; 2012 Apr; 132(2):421-8. PubMed ID: 21614564
[TBL] [Abstract][Full Text] [Related]
35. Identification of germline BRCA1 mutations among breast cancer families in Northeastern Iran.
Kooshyar MM; Nassiri M; Mahdavi M; Doosti M; Parizadeh A
Asian Pac J Cancer Prev; 2013; 14(7):4339-45. PubMed ID: 23992000
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer.
Chappuis PO; Hamel N; Paradis AJ; Deschênes J; Robidoux A; Potvin C; Cantin J; Tonin P; Ghadirian P; Foulkes WD
Clin Genet; 2001 Jun; 59(6):418-23. PubMed ID: 11453973
[TBL] [Abstract][Full Text] [Related]
37. Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
Ditchi Y; Broudin C; El Dakdouki Y; Muller M; Lavaud P; Caron O; Lejri D; Baynes C; Mathieu MC; Salleron J; Benusiglio PR
Breast J; 2019 Jan; 25(1):16-19. PubMed ID: 30414230
[TBL] [Abstract][Full Text] [Related]
38. [BRCA1- and BRCA2- associated breast carcinomas].
Ahrens P; Kreipe HH
Pathologe; 2009 Dec; 30 Suppl 2():207-9. PubMed ID: 19795125
[TBL] [Abstract][Full Text] [Related]
39. Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.
Turkovic L; Gurrin LC; Bahlo M; Dite GS; Southey MC; Hopper JL
BMC Cancer; 2010 Sep; 10():466. PubMed ID: 20807450
[TBL] [Abstract][Full Text] [Related]
40. BRCA-associated breast cancer: absence of a characteristic immunophenotype.
Robson M; Rajan P; Rosen PP; Gilewski T; Hirschaut Y; Pressman P; Haas B; Norton L; Offit K
Cancer Res; 1998 May; 58(9):1839-42. PubMed ID: 9581822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
